Figure 1 | British Journal of Cancer

Figure 1

From: Phase Ib study of NGR–hTNF, a selective vascular targeting agent, administered at low doses in combination with doxorubicin to patients with advanced solid tumours

Figure 1

Incidence of grade 3–4 adverse events by dose levels. For each dose level of asparagine–glycine–arginine–human tumour necrosis factor (NGR-hTNF) and doxorubicin the following number of cycles were administered, respectively: 0.2–60 : 12–12; 0.2–75 : 27–17; 0.4–75 : 13–11; 0.8–75 : 25–12; 1.6–75 : 12–10.

Back to article page